Xu, Tong
Verhagen, Mathijs P. http://orcid.org/0000-0003-3126-8379
Teeuwssen, Miriam
Sun, Wenjie
Joosten, Rosalie
Sacchetti, Andrea
Ewing-Graham, Patricia C.
Jansen, Maurice P. H. M.
Boere, Ingrid A.
Bryce, Nicole S.
Zeng, Jun
Treutlein, Herbert R.
Hook, Jeff
Hardeman, Edna C. http://orcid.org/0000-0003-1649-7712
Gunning, Peter W. http://orcid.org/0000-0003-0833-3128
Fodde, Riccardo http://orcid.org/0000-0001-9839-4324
Funding for this research was provided by:
China Scholarship Council (201806300047, 201806300047)
KWF Kankerbestrijding (2015-8090)
Department of Health | National Health and Medical Research Council (APP1079866, APP1100202, APP1079866, APP1100202)
Article History
Received: 24 July 2023
Revised: 1 February 2024
Accepted: 6 February 2024
First Online: 16 February 2024
Competing interests
: PWG and ECH receive funding from and are Directors of TroBio Therapeutics, a company commercializing anti-tropomyosin drugs. The remaining authors declare no competing interests.